Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany

Wefer, B.; Ehlken, B; Bremer, J.; Burgdörfer, H.; Domurath, B.; Hampel, Harald; Kutzenberger, J.; Seif, C.; Sievert, Karl Dietrich; Berger, Karin; Pannek, Jürgen

doi:10.1007/s00345-009-0466-1

Cited by 49 publications

(28 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, although little is known regarding the pathology of low-compliance and break-low-compliance, data from this study suggest that BoNT-A treatment may beneWt these NBD as well. The frequency of micturition or clean intermittent catheterisation as well as the number of incontinence episodes was satisfactorily improved after BoNT-A (Botox ® ), conWrming previous Wndings [8,19,[24][25][26][27].…”

Section: Discussionsupporting

confidence: 55%

Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment

Alloussi

Ch²,

Eichel³

et al. 2011

World J Urol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 55%

Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment

Alloussi

Ch²,

Eichel³

et al. 2011

World J Urol

View full text Add to dashboard Cite

show abstract

“…Only 3 of 30 patients had symptomatic UTIs after injection, and they presented the least improvement in urodynamic parameters. Further retrospective studies with longer follow-up (1-6 years) confirmed the reduced incidence of UTIs, even after repeat BoNT/A injections [53•], resulting in decreased treatment costs [58]. Finally, a lack of association between BoNT/A and UTIs was concluded by the similar rate of UTIs between the placebo and the active drug population in the randomized controlled trial in NDO patients [17].…”

Section: Urinary Tract Infectionsmentioning

confidence: 83%

Current Status of Botulinum Toxin for Neurogenic Bladder Dysfunction

Oeconomou

Apostolidis

2010

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

With 10 years of use completed since the first bladder injection, an increasing body of evidence supports the efficacy of intradetrusally injected botulinum neurotoxin type A to treat intractable symptoms of neurogenic detrusor overactivity in adults. Highly significant improvements in patients' symptoms, urodynamic parameters and quality of life, sustained with repeat injections and with few transient side effects have been consistently reported, leading to high-grade recommendations for its use in refractory adult neurogenic detrusor overactivity. Cautions have been raised when it is used in children, in whom efficacy has been shown in open-label studies. Large, placebo-controlled trials are awaited, as is further investigation into long-term safety.

show abstract

“…With the authors' model assuming a 6-month interval for repeated BoNT-A injections at the 200-U dose, the cost analysis revealed that BoNT-A was the least expensive of the three options. In 2010, Wefer et al [30] performed a European cost analysis as part of their report of 214 patients that also revealed a cost savings in incontinence aids and treatment of urinary tract infections.…”

Section: Cost Analysismentioning

confidence: 98%

Current Use of Botulinum A Toxin in Overactive Bladder Management

Spettel

Welliver

2011

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Overactive bladder (OAB), which is refractory to oral medications, is a challenging condition. Patients with refractory idiopathic OAB often have severe symptoms and impaired quality of life. Those with neurogenic bladder carry the potential for high voiding pressures and damage to their upper and lower urinary tract. Botulinum A toxin, injected under cystoscopic guidance, offers a promising, reversible, acceptably invasive treatment option. A growing body of research has demonstrated its effectiveness in reducing OAB symptoms, improving both urodynamic parameters and quality-of-life measures. However, the potential for inadvertent urinary retention (impacting primarily the idiopathic group) and need for repeat cystoscopic administration limit its acceptability. Although important questions surrounding use remain, botulinum A toxin injections can provide a well-tolerated, minimally invasive alternative treatment for the management of refractory OAB. This review focuses on the published literature from the past year.

show abstract

Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany

Abstract: This is the first study demonstrating the clinical usefulness of Botox therapy in clinical practice. Successful treatment resulted in lower costs for NDO associated morbidity due to less need for incontinence aids and UTI medication.

Cited by 49 publications

References 21 publications

Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment

Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment

Current Status of Botulinum Toxin for Neurogenic Bladder Dysfunction

Current Use of Botulinum A Toxin in Overactive Bladder Management

Contact Info

Product

Resources

About